1. ALLA AKTIER
  2. NYHETER
  3. XINTELA

Xintela

Nyheter Xintela Nyheter alla bolag

Xintela AB Interim Report January - March 2024

MARKN.

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

First quarter 2024 for the group
Income amounted to TSEK 299 (0).
Loss before tax totalled TSEK 11,372 (loss: 15,843).
Loss per share was SEK 0.02 (loss: 0.05).

First quarter 2024 for the parent company
Income amounted to TSEK 299 (0).
Loss before tax totalled TSEK 9,688 (loss: 10,403).
Loss per share was SEK 0.02 (loss: 0.03).
At March 31, 2024, the equity/assets ratio was 52 % (45).

Significant events in the first quarter of 2024
Xintela appoints Lucienne Vonk as Chief Scientific Officer. (February 19, 2024)

Significant events after the end of the period
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses. (May 23, 2024)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

Xintela 2024 Q1 EN

Datum 2024-05-24, kl 08:00
Källa MFN
Bifogade filer
Xintela 2024 Q1 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!